Celldex Therapeutics, Inc. $CLDX Stock Position Raised by Rhumbline Advisers

Rhumbline Advisers lifted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 6.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 98,266 shares of the biopharmaceutical company’s stock after acquiring an additional 6,327 shares during the quarter. Rhumbline Advisers owned approximately 0.15% of Celldex Therapeutics worth $1,784,000 as of its most recent filing with the SEC.

Other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC increased its stake in Celldex Therapeutics by 6,665.9% in the 1st quarter. GAMMA Investing LLC now owns 2,977 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 2,933 shares during the period. Ameriprise Financial Inc. acquired a new position in Celldex Therapeutics in the 4th quarter valued at approximately $251,000. AlphaQuest LLC increased its stake in Celldex Therapeutics by 182.5% in the 1st quarter. AlphaQuest LLC now owns 12,112 shares of the biopharmaceutical company’s stock valued at $220,000 after buying an additional 7,825 shares during the period. ADAR1 Capital Management LLC acquired a new position in Celldex Therapeutics in the 1st quarter valued at approximately $265,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH acquired a new position in Celldex Therapeutics in the 1st quarter valued at approximately $269,000.

Analysts Set New Price Targets

Several research analysts have weighed in on CLDX shares. Citigroup dropped their price objective on shares of Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating on the stock in a research note on Wednesday, August 20th. HC Wainwright dropped their price objective on shares of Celldex Therapeutics from $50.00 to $42.00 and set a “buy” rating on the stock in a research note on Wednesday, August 20th. Wells Fargo & Company dropped their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 20th. Finally, Canaccord Genuity Group restated a “buy” rating and set a $62.00 price target on shares of Celldex Therapeutics in a research note on Wednesday. Seven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $46.67.

Celldex Therapeutics Price Performance

Shares of Celldex Therapeutics stock opened at $25.92 on Friday. Celldex Therapeutics, Inc. has a fifty-two week low of $14.40 and a fifty-two week high of $47.00. The firm has a fifty day moving average price of $22.99 and a two-hundred day moving average price of $20.86. The company has a market cap of $1.72 billion, a PE ratio of -8.61 and a beta of 1.19.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.01. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. The firm had revenue of $0.73 million during the quarter, compared to the consensus estimate of $1.13 million. Analysts expect that Celldex Therapeutics, Inc. will post -2.48 earnings per share for the current fiscal year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.